AbbVie Inc. (ABBV): Billionaire Ken Fisher Admires This Pharma Stock

AbbVie Inc. (NYSE:ABBV) is one of Billionaire Ken Fisher’s 15 Most Notable Moves for 2026.

AbbVie Inc. (NYSE:ABBV) is a constant part of the 13F portfolio of Fisher Asset Management since the start of 2013. Even though the fund trimmed this stake substantially around 2020, it has started buying shares of the company again since early 2025. In the last quarter of 2025, the fund upped the stake in AbbVie by 128% compared to third quarter filings. The holding now comprises close to 630,000 shares. In 2021, just after trimming his stake in AbbVie, Fisher had acknowledged that in recent years, the prospect of major drug pricing reform in the US had weighed on pharmaceutical and healthcare stocks.

However, Fisher is also an admirer of pharma giants like AbbVie Inc. (NYSE:ABBV) because he has often made the argument over the past decades that the government does not have the ability to set broad drug prices for everyone across the US without congressional approval. This indicates that Fisher understands how political gridlock limits sweeping drug-price regulation in the US, which can reduce long-term risk for pharmaceutical stocks. Improved medicine and rising wealth are two other factors providing tailwind to pharma firms as life expectancy increases across the developed north.

AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical company that engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.